Abstract: The present invention relates to cells engineered to express at least one cytokine and at least one antigen which induces the self differentiation of dendritic cell (DC) progenitor cells into functional antigen-presenting induced DC (iDC). Moreover, therapeutic uses of said iDC for regenerating the immune system after transplantation of hematopoietic stem cells are disclosed. Said iDC are also useful for generating mice with a functional endogenously regenerated humanized immune system producing antigen-specific T and B cell responses which can be used as animal models for the study of the human adaptive immune responses.
Type:
Grant
Filed:
April 26, 2019
Date of Patent:
August 16, 2022
Assignee:
MEDIZINISCHE HOCHSCHULE HANNOVER
Inventors:
Renata Stripecke, Gustavo Salguero-Lopez, Anusara Daenthanasanmak, Arnold Ganser
Abstract: Herein a Bacillus exosporium antigen delivery (BEAD) system that provides a means to introduce recombinant proteins or small molecules into the exosporium of members of the B. cereus family of bacteria, i.e. B. anthracis, B. cereus, and B. thuringiensis, is disclosed. The system results in the surface display of recombinant proteins or small molecules such that they can stimulate an immune response. In addition, methods of making and using the system are described.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
August 2, 2022
Assignee:
The Curators of the University of Missouri
Inventors:
George C. Stewart, Brian Matthew Thompson
Abstract: A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.
Type:
Grant
Filed:
April 22, 2021
Date of Patent:
July 19, 2022
Assignee:
CRISPR Therapeutics AG
Inventors:
Mark Benton, Tony Ho, Demetrios Kalaitzidis, Ewelina Morawa, Jonathan Alexander Terrett
Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.
Type:
Grant
Filed:
June 8, 2020
Date of Patent:
July 19, 2022
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITE DE ROUEN, TARGEDYS
Inventors:
Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Naouel Tennoune, Romain Legrand
Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Type:
Grant
Filed:
September 8, 2016
Date of Patent:
July 12, 2022
Assignee:
SYNLOGIC OPERATING COMPANY, INC.
Inventors:
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
Abstract: Formulations comprising anionic agents such as nucleic acids within a lipid-containing particle methods of formulating a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for preparing a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for therapeutic delivery of an anionic agent to a patient in need thereof, where the anionic agent is formulated in a lipid-containing particle as described herein.
Abstract: An in vitro method for integrating an exogenous DNA sequence into the genome of a cell using a transposon system. The transposon system includes a first vector carrying inverted repeat sequences and an exogenous DNA, and a second vector that expresses a transposases. Also provided is a kit including the transposon system for integrating an exogenous DNA into the genome of a cell. A method for treating a subject is described that includes engineering an immune cell to carry an exogenous DNA sequence using the method and/or the kit described above and administering an effective amount of the engineered immune cell to the subject.
Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Type:
Grant
Filed:
April 12, 2021
Date of Patent:
April 12, 2022
Assignee:
CRISPR Therapeutics AG
Inventors:
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Abstract: A method of treating cancer can include administering a polyplex of a double stranded RNA and a polymeric conjugate. The polymeric conjugate can consist of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety can be conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.
Abstract: Described herein are carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a nitroboronic boronic acid and a linkage cleavable under reducing conditions, configured to present the polymer containing the nitroboronic acid to an environment external to the nanoparticle. Targeted versions of the described nanoparticles are also described, as are related compositions, methods and systems.
Abstract: Engineered MREG proteins are described. Further described are viral vectors expressing native or engineered MREG proteins. Further described are compositions containing these vectors or proteins formulated for delivery to the eye. Also provided are methods for delivering these native and engineered MREG proteins to ocular cells for treatment of Stargardt's disease, macular degeneration and other ocular disorders.
Type:
Grant
Filed:
October 7, 2016
Date of Patent:
March 15, 2022
Assignee:
The Trustees of the University of Pennsylvania
Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.
Type:
Grant
Filed:
May 31, 2017
Date of Patent:
March 15, 2022
Assignees:
Summa Health, Northeast Ohio Medical University
Inventors:
Marc S. Penn, Matthew Kiedrowski, Maritza Mayorga
Abstract: Disclosed are products and methods for therapy using nucleic acid molecules, and in particular in relation to treatment of alpha-1-antitrypsin deficiency. Also disclosed are pharmaceutical compositions including the nucleic acids and/or delivery vehicles including the nucleic acids, and their use in manufacture of pharmaceutical compositions for use in therapy, such as treatment of alpha-1-antitrypsin deficiency.
Abstract: The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.
Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Type:
Grant
Filed:
November 5, 2020
Date of Patent:
February 8, 2022
Assignee:
LENTIGEN TECHNOLOGY, INC.
Inventors:
Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
Abstract: The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject.
Type:
Grant
Filed:
January 23, 2019
Date of Patent:
February 1, 2022
Assignee:
IMMUNOVACCINE TECHNOLOGIES INC.
Inventors:
Marc Mansour, Mohan Karkada, Genevieve Mary Weir
Abstract: Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.
Type:
Grant
Filed:
January 21, 2016
Date of Patent:
January 11, 2022
Assignee:
Genevant Sciences GmbH
Inventors:
Mary G. Prieve, Michael E. Houston, Jr., Pierrot Harvie, Sean D. Monahan
Abstract: Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.
Type:
Grant
Filed:
October 8, 2018
Date of Patent:
January 4, 2022
Assignee:
Edwards Lifesciences Corporation
Inventors:
Jeffrey S. Dove, Bin Tian, Ralph Schneider, Jeffrey S. Cohen, Ivan Jankovic, John F. Migliazza, Gregory A. Wright, James M. Young, Louis A. Campbell
Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Type:
Grant
Filed:
April 12, 2021
Date of Patent:
December 28, 2021
Assignee:
CRISPR Therapeutics AG
Inventors:
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein